Metagenomi Therapeutics (MGX) Stock Price, Quote, News & History | Benzinga

Metagenomi Therapeutics Inc (MGX) Stock Price, Quote, News & History

MGXNASDAQ

Trade with Public

Trade with Public

$1.16

N/A

At close: Sep 3, 5:00 PM EST

$1.20

0.043.45%

After Hours: Sep 1, 7:24 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$1.20

Close

$1.16

Volume / Avg.

69.01K / 162.24K

Day Range

$1.15 - $1.21

52 Wk Range

1.13 - 3.95

Market Cap

$45.33M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

38

Short Interest

4.74%

Days to Cover

10.98

Recent Metagenomi Therapeutics Inc News

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce

Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027.

Vandana Singh

Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' Jibe

OpenAI CEO Sam Altman regrets underestimating Elon Musk's potential abuse of power to block OpenAI's $500B Stargate deal. Tensions also rise with Microsoft.

Shomik Sen Bhattacharjee

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Vandana Singh

Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

Avi Kapoor

Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-85.49M

Investing Cash Flow (TTM)

96.88M

Financing Cash Flow (TTM)

-73.00K

Free Cash Flow (TTM)

-85.80M

Capital Expenditure (TTM)

-309.00K

Net Change in Cash (TTM)

11.32M

Analyst Trends and Forecast

1

May

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$39.12M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.21

PB Ratio (TTM)

0.39

Earnings Yield % (TTM)

-214.66%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.98

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$39.03M

Debt to Equity

0.34

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.20

Close

$1.16

Volume / Avg.

69.01K / 162.24K

Day Range

$1.15 - $1.21

52 Wk Range

1.13 - 3.95

Market Cap

$45.33M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

38

Short Interest

4.74%

Days to Cover

10.98

About

Sector

Health Care

Industry

Biotechnology

Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Metagenomi Therapeutics (MGX) stock?

A

You can purchase shares of Metagenomi Therapeutics (NASDAQ:MGX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Metagenomi Therapeutics (MGX) competitors?

A

Other companies in Metagenomi Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Metagenomi Therapeutics (MGX) stock?

A

Metagenomi Therapeutics has a consensus price target of $10.38.

Q

What is the current price for Metagenomi Therapeutics (MGX)?

A

The stock price for Metagenomi Therapeutics (NASDAQ: MGX) is $1.2 last updated September 1, 2026 at 7:24 AM EDT.

Q

Does Metagenomi Therapeutics (MGX) pay a dividend?

A

There are no upcoming dividends for Metagenomi Therapeutics.

Q

When is Metagenomi Therapeutics (NASDAQ:MGX) reporting earnings?

A

Metagenomi Therapeutics does not have any upcoming earnings scheduled.

Q

Is Metagenomi Therapeutics (MGX) going to split?

A

There is no upcoming split for Metagenomi Therapeutics.

Q

What sector and industry does Metagenomi Therapeutics (MGX) operate in?

A

Metagenomi Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.